QR Kod

Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma

Synovial sarcoma tumours contain a characteristic fusion protein, SS18-SSX, which drives disease development. Targeting oncogenic fusion proteins presents an attractive therapeutic opportunity. However, SS18-SSX has proven intractable for therapeutic intervention. Using a domain-focused CRISPR scree...

Ful tanımlama

Kaydedildi:
Asıl Yazarlar: Gerard L Brien, David Remillard, Junwei Shi, Matthew L Hemming, Jonathon Chabon, Kieran Wynne, Eugène T Dillon, Gerard Cagney, Guido Van Mierlo, Marijke P Baltissen, Michiel Vermeulen, Jun Qi, Stefan Fröhling, Nathanael S Gray, James E Bradner, Christopher R Vakoc, Scott A Armstrong
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: eLife Sciences Publications Ltd 2018-11-01
Seri Bilgileri:eLife
Konular:
synovial sarcoma
SWI/SNF
BRD9
targeted degradation
SS18-SSX
fusion protein
Online Erişim:https://elifesciences.org/articles/41305
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller